Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates
|
|
- Garry Wood
- 6 years ago
- Views:
Transcription
1 cp60392 Module 1 Journal of Clinical Pathology 28/8/08 12:38:20 Topics: ; Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates M Romano, 1 M R Iovene, 2 M I Russo, 1 A Rocco, 3 R Salerno, 1 D Cozzolino, 1 A P Pilloni, 2 M A Tufano, 2 D Vaira, 4 G Nardone 3 1 Dipartimento Medico- Chirurgico di Internistica Clinica e Sperimentale, Gastroenterologia, Seconda Università di Napoli, Naples, Italy; 2 Microbiologia Clinica, Seconda Università di Napoli, Naples, Italy; 3 Dipartimento di Medicina Clinica e Sperimentale- Gastroenterologia, Università Federico II di Napoli, Naples, Italy; 4 Dipartimento di Medicina Interna e Gastroenterologia, Ospedale S. Orsola, Università of Bologna, Bologna, Italy Correspondence to: Professor G Nardone, Dipartimento di Medicina Clinica e Sperimentale, Unità di Gastroenterologia, via Pansini 5, Naples, Italy; nardone@unina.it Accepted 15 August 2008 Published Online First XXXX ABSTRACT Objectives: Helicobacter pylori infection is a major health problem worldwide, and effective eradication of the infection is mandatory. The efficacy of recommended eradication regimens is approximately 70%. In order to avoid treatment failure and the consequent development of secondary resistance(s), it is important to choose the most appropriate first-line treatment regimen. This choice should also be made based on the knowledge of the antimicrobial resistance peculiar to a given geographical area. We evaluated the prevalence of antimicrobialresistant H pylori strains isolated from naive patients and from patients with previous unsuccessful treatments. Methods: We studied 109 H pylori-infected subjects (Group 1) who had never received an eradication treatment and 104 H pylori-infected subjects (Group 2) who had failed one or more eradication treatments. Resistance to amoxicillin (AMO), tetracycline (TET), clarithromycin (CLA), metronidazole (MET) and levofloxacin (LEV) was determined using the epsilometer test. The significance of differences was evaluated by the x 2 test. Results: The prevalence of antimicrobial resistance was 0% versus 3.1% to AMO, 0% versus 2% to TET, 27% versus 41.3% to MET (p,0.05), 18% versus 45.8% to CLA (p,0.05) and 3% versus 14.6% to LEV (p,0.05) in Group 1 vs Group 2, respectively. In Group 2, there was an increased prevalence of H pylori strains resistant to multiple antimicrobials. Conclusions: This study confirms the high prevalence of H pylori strains resistant to CLA and MET, and indicates that unsuccessful treatments significantly increase resistance. Choosing eradication regimens other than standard triple therapy as a first-line therapy should be advisable in areas with high primary antimicrobial resistance prevalence. Helicobacter pylori is the major aetiological agent of chronic gastritis, peptic ulcer disease, gastric MALT lymphoma and gastric cancer. 1 2 Thus, once H pylori infection is diagnosed, it should be treated. In the last 20 years, standard triple therapy (ie, PPI, amoxicillin and clarithromycin/or metronidazole) has been largely adopted in various geographical regions worldwide and quoted as first-choice therapy by the Maastricht I and II consensus report. 3 4 However, standard triple therapy, like other available antimicrobial therapies for H pylori infection, has limited efficacy, because of side effects with poor compliance of patients to therapy and, more importantly, because of the development of antimicrobial resistance. The increasing prevalence of H pylori strains resistant to commonly used antimicrobials together with the lack of novel treatment options negatively affects eradication of H pylori infection, which is now approximately 70% and may lead to serious problems for the treatment of H pylori-related disorders in the near future. In recent years, the progressive decline in the eradication rate for H pylori has paralleled an increased rate of development of clarithromycin and metronidazole-resistant strains. 5 A systematic review of literature on eradication therapy indicated a 53% decrease in eradication rates of H pylori infection if clarithromycin resistance was present, and a clarithromycin-containing regimen was used. 6 Therefore, because clarithromycin resistance seems to be the most important limiting factor for treatment failure, 7 8 the prevalence of this resistance should be recognised before choosing the H pylori eradication regimen. The overall rate of clarithromycin resistance in Europe is 10%, ranging from 4% in northern European countries to 18.5% in southern European countries. The different prevalence in clarithromycin resistance depends mainly on the consumption of macrolides in the corresponding countries as expressed by measuring the daily dose of macrolides per 1000 inhabitants. 9 The recent Maastricht III consensus has recommended that the threshold of clarithromycin resistance at which this antibiotic should not be used or a susceptibility test performed is 15 20%. 10 Should this be the case, quadruple therapy represents the first-choice therapy. Failure of first-line therapy may contribute to the development of secondary resistance or resistance to multiple antimicrobials. This further hampers the efficiency of eradication therapy and strongly limits the number of effective antimicrobials available for eradication. This study, therefore, sought to investigate the prevalence of H pylori strains resistant to the antimicrobials commonly used for eradication (ie, clarithromycin, metronidazole, amoxicillin, levofloxacin and tetracycline). To this purpose, we studied H pylori clinical isolates obtained from H pylori-infected patients who had never been treated and H pylori isolates obtained from patients with one or more previous unsuccessful treatments. PATIENTS AND METHODS We consecutively enrolled 109 H pylori-infected patients (59 men and 50 women, age range years) (Group 1) who had never received an J Clin Pathol 2008;000:1 5. doi: /jcp
2 cp60392 Module 1 Journal of Clinical Pathology 28/8/08 12:38:21 Topics: < = eradication treatment and 104 H pylori positive patients (56 men and 48 women, age range years) (Group 2) who had failed one or more eradication treatments, referred to the Gastroenterology Units of the University of Naples because of dyspeptic symptoms. For histology, we took two biopsy specimens from the antrum, two from the body and one from the angulus; diagnosis and grading of gastritis were made according to the updated Sidney system. 11 One biopsy specimen was taken from the antrum and one from the body for a rapid urease test. Diagnosis of H pylori infection was based on positivity to both histology and 13 C urea breath test. Patients gave their written informed consent to enter the study, which was approved by the Ethical Committee of the Second University and the Federico II University of Naples, Italy. Bacterial culture and antimicrobial susceptibility testing Biopsy specimens were cultured in Helicobacter-selective agar at 37uC in microaerophilic atmosphere (O 2 5%, CO 2 5%, Campygen Oxoid) for 3 6 days as previously described. H pylori was identified by Gram staining and by oxidase and catalase and urease reactions. All isolates identified as H pylori were subcultured in Helicobacter-selective agar at 37uC in a microaerophilic atmosphere for 3 6 days. From each subculture, a suspension in Brucella broth (2 ml) supplemented with fetal bovine serum (2%), yielding a viable count of 108 to 109 colonyforming units/ml, equivalent to 3 4 McFarland turbidity standard, was prepared. From each suspension, 100 ml was transferred onto the surface of a Mueller-Hinton agar plate with 5% sheep blood and streaked with a cotton swab. Subsequently, two antibiotic strips (E test) were applied onto the surface of each dried agar plate. After incubation, in a microaerophilic atmosphere at 37uC for 3 6 days, the concentration shown in the E test strip that was closest to the intersection point with growth on the plate (ie, the lowest concentration of drug inhibiting visible bacterial growth) was defined as minimal inhibitory concentration (MIC). E test strips containing amoxicillin (AMO), levofloxacin (LEV), tetracycline (TET), clarithromycin (CLA) and metronidazole (MET) were used. MICs are expressed in mg/l. Statistical analysis We set the power of the study to 0.8, I type error = 0.05 and control to case 1:1. The aim was to detect a minimal difference of 10% between the two groups. Data were analysed with the SPSS package for Windows (SPSS, Chicago). The significance of differences was assessed by x 2 test, and the level of significance was set at p,0.05. RESULTS The endoscopic, histological and serological findings in all 150 patients are summarised in table 1. Both groups showed comparable (ie, not statistically different) prevalence of endoscopic and histological alterations. Also, the prevalence of anti-caga positivity was not statistically different in the two groups of patients. Culture and in vitro antimicrobial susceptibility testing was unsuccessful in nine patients of Group 1 and in eight patients in Group 2. MIC values for each antimicrobial tested in Group 1 and Group 2 are shown in table 2. Table 3 shows the prevalence of antimicrobial resistance in Group 1 (100 subjects) and in Group 2 (96 subjects). In particular, the prevalence of antimicrobial resistance (n%) of H pylori in Group 1 (n = 100) was 0 (0%) to amoxicillin, 0 (0%) to tetracycline, 27 (27%) to metronidazole, 18 (18%) to clarithromycin and 3 (3%) to levofloxacyn. Prevalence of antimicrobial resistance (n%) in Group 2 (n = 96) was 3 (3.1%) to amoxicillin, 2 (2.1%) to tetracycline, 40 (41.3%) to metronidazole, 44 (45.8%) to clarithromycin and 14 (14.6%) to levofloxacin. The prevalence of resistance to clarithromycin, metronidazole or levofloxacin was significantly higher in patients who had already been treated compared with those who had never received an eradication treatment (table 3). Five subjects in Group 1 were resistant to both clarithromycin and metronidazole, whereas in Group 2 (ie, following unsuccessful eradication treatment), the prevalence of multiple resistance was much higher, with 21 subjects being resistant to both clarithromycin and metronidazole, five subjects to clarithromycin, metronidazole and levofloxacin, two subjects to clarithromycin and levofloxacin, two subjects to metronidazole and levofloxacyn, one subject to all antimicrobials but tetracycline and one subject to all of the antimicrobials tested (table 4). DISCUSSION This study shows that in a restricted area of southern Italy, there is an increased prevalence of H pylori strains which are resistant to commonly used antimicrobials. Also, previous treatment failures seem to greatly increase the rate of antimicrobial resistance of H pylori clinical isolates and favour the development of H pylori strains which are resistant to more than one antimicrobial. The management of H pylori-related gastroduodenal diseases strictly relies on the eradication of the infection. This is accomplished in 70 80% of cases through a therapeutic regimen based on the association between a proton-pump inhibitor (PPI) and two antimicrobials (ie, clarithromycin and amoxicillin) as first-line therapy Lack of 100% efficacy of commonly used eradication regimens depends on several factors. The location of the bacterium within the stomach (ie, the mucus lining the surface epithelium or the surface of mucous cells) provides a challenge for antimicrobial therapy. Also, the gastric lumen is a hostile environment for antimicrobial therapy because the drug must penetrate a thick mucous and may need to be active at a ph value below neutral. Moreover, compliance to therapy is hampered by the frequent occurrence of antimicrobial-related side effects. Finally, the number of H pylori strains resistant to common antimicrobials is increasing. 15 Therefore, choosing the most appropriate first-line therapy is crucial in order to eradicate the infection and to avoid the emergence of secondary antimicrobial resistance. Our study performed in an Italian region with a high prevalence of H pylori infection indicates that the primary resistance to the antimicrobials which are routinely used in the treatment of the infection is becoming unacceptably high. In particular, clarithromycin resistance is approximately 20%, thus suggesting that, at least in this geographical area, this antimicrobial should not be included in the first-line therapy of the infection. The reasons for high clarithromycin resistance are not completely known. One may hypothesise that because of its efficacy and good tolerability, this antimicrobial is largely used especially in the treatment of upper-airways infections in childhood, thus increasing the likelihood of resistance. The clinical effect of clarithromycin resistance is essentially complete loss of any anti-h pylori effect, and the outcome of therapy can generally be predicted on the basis of what could be expected if only the other antimicrobial(s) in the regimens were used. 16 Based on this, in the Maastricht III consensus conference on H pylori, it was stated that in areas with a clarithromycin 2 J Clin Pathol 2008;000:1 5. doi: /jcp
3 cp60392 Module 1 Journal of Clinical Pathology 28/8/08 12:38:21 Topics: Table 1 Endoscopic, histological and serological characteristics of patients in naïve (Group 1) and previously treated (Group 2) patients n (%) n (%) Endoscopy Erosions Erythema Duodenal ulcer 3 2 Histology Chronic gastritis Mild Moderate Severe Activity Mild Moderate Severe Atrophy Mild Moderate 5 8 Severe 4 6 Metaplasia Mild 9 10 Moderate 4 5 Severe 1 1 Helicobacter pylori density Mild Moderate Severe Anti-CagA positive resistance between 15% and 20%, clarithromycin should not be used unless a pretreatment antimicrobial susceptibility testing is performed. In this regard, we have previously demonstrated that, at least in patients undergoing an upper endoscopy, performing culture and pretreatment antimicrobial susceptibility testing increases the efficacy of first-line therapy and is also cost-saving, decreasing the need for re-treatment and retesting. 17 Our study also confirms a high prevalence of primary resistance to metronidazole which is as high as 27%. This figure increases to 40% in patients who have already been treated for H pylori infection without achieving eradication of the infection. However, increasing the dosage of metronidazole administered (i.e from 1 to 1.5 g/day) generally improves the results of therapy when treating metronidazole-resistant H pylori strains. Levofloxacin-based triple therapy has recently been used and suggested as a successful rescue treatment following failure of Table 3 Prevalence of antimicrobial resistance in Group 1 (naïve Helicobacter pylori patients) and Group 2 (Helicobacter pylori-infected patients with previous unsuccessful treatments) Resistance n (%) Resistance n (%) p Value Amoxicillin 0 (0) 3 (3.1) NS Tetracycline 0 (0) 2 (2.1) NS Metronidazole 27 (27) 40 (41.3) 0.03 Clarithromycin 18 (18) 44 (45.8), Levofloxacyn 3 (3) 14 (14.6) 0.04 first-line therapy Interestingly, in our study, primary resistance to levofloxacin is approximately 3%, thus making this antimicrobial suitable to be used in first-line therapy as an alternative to clarithromycin in areas with a high prevalence of primary resistance to this antimicrobial. Secondary resistance develops as the result of failed therapy. In fact, in our study, there is a statistically significant increase in the resistance toward all of the antimicrobials tested following one or more treatment failures. In particular, there was a fold increase in metronidazole resistance, a 2.4-fold increase in clarithromycin resistance and a 4.6-fold increase in levofloxacin resistance. Moreover, there was the appearance of amoxicillinand tetracycline-resistant strains, even though the prevalence was as low as 3% and 2%, respectively. More interestingly, following unsuccessful eradication treatments, there was the appearance of several H pylori strains resistant to more than one antimicrobial. In particular, one patient was resistant to four antimicrobials and one other patient to all of the antimicrobials tested. This indicates that other effective antimicrobials or drugs which interfere with metabolic pathways necessary for the survival of the bacterium are needed. Recently, potential developments in anti-h pylori treatment have been made, suggesting that antimicrobial peptides, 20 essential oils, 21 porphyrins 22 and probiotics 20 may be promising but still far from being used in clinical practice. Also, sequential therapy using PPI and amoxicillin for 5 days followed by PPI plus clarithromycin and tinidazole for 5 more days. > 23 This regimen has been reported to achieve a near 95% success rate, 23 also in children. 24 Alternatively, in subjects undergoing an upper endoscopy, pretreatment susceptibility testing might prove to be of use. 17 In conclusion, this study indicates that in our region there is a large prevalence of H pylori strains resistant to clarithromycin and metronidazole. Therefore, in this setting, choosing quadruple therapy or levofloxacin-based triple therapy as a first-line eradication regimen should be advisable. Also, our study indicates that secondary resistance, even to multiple antimicrobials, is becoming a major problem in the management of Table 2 Group 2 Comparative activity of the antimicrobials tested against Helicobacter pylori isolates in Group 1 and E test range (mg/l) MIC50 (mg/l) MIC90 (mg/l) E test range (mg/l) MIC50 (mg/l) MIC90 (mg/l) Amoxicillin 0016 to to Metronidazole 0016 to to Clarithromycin 0016 to to Tetracycline 0016 to to Levofloxacyn 0002 to to MIC50 values ranged from mg/ml for amoxicillin to.32 mg/ml for metronidazole. MIC50, minimal inhibitory concentration required to inhibit the growth of 50% of organisms; MIC90, minimal inhibitory concentration required to inhibit the growth of 90% of organisms. J Clin Pathol 2008;000:1 5. doi: /jcp
4 cp60392 Module 1 Journal of Clinical Pathology 28/8/08 12:38:25 Topics: Table 4 Prevalence of multiple antimicrobial resistance in Group 1 (ie, naïve Helicobacter pylori patients) and Group 2 (ie, Helicobacter pyloriinfected patients with previous unsuccessful treatments) Resistance n (%) Resistance n (%) MET+CLA 5 (5) 21 (21.8) CLA+LEV 0 2 (2.1) MET+LEV 0 2 (2.1) MET+CLA+LEV 0 5 (5.2) MET+CLA+LEV+AMO 0 1 (1.04) MET+CLA+LEV+AMO+TET 0 1 (1.04) AMO, amoxicillin; CLA, clarithromycin; LEV, levofloxacin; MET, metronidazole; TET, tetracycline. H pylori infection and suggests that the very low efficiency of rescue treatments might be due to increased secondary resistance to almost all of the antimicrobials available for H pylori eradication. This further strengthens the concept that the best rescue regimen should be a near to 100% efficient first-line therapy. Competing interests: None. Ethics approval: Ethics approval was provided by the Ethical Committee of the Second University and the Federico II University of Naples, Italy. Patient consent: Obtained. REFERENCES 1. Zarrilli R, Ricci V, Romano M. Molecular response of gastric epithelial cells to Helicobacter pylori-induced damage. Cell Microbiol 1999;1: Romano M, Ricci V, Zarrilli R. Helicobacter pylori-related gastric carcinogenesis implications for chemoprevention. Nat Clin Pract Gastroenterol Hepatol 2006;3: Malfertheiner P, Megraud F, O Morain C, et al. Current European concepts in the management of Helicobacter pylori infection: the Maastricht Consensus Report. The European Helicobacter pylori Study Group. Eur J Gastroenterol Hepatol 1997;9: Malfertheiner P, Megraud F, O Morain C, et al. European Helicobacter pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection: the Maastricht Consensus Report. Aliment Pharmacol Ther 2002;16: Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53: Vergara M, Catalan M, Gisbert JP, et al. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005;21: Megraud F, Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2003;17: McMahon BJ, Hemmessy TW, Bensler JM, et al. The relationship among previous antimicrobial use, antimicriobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 2003:139: Cars O, Molstad S, Melander A. Variation in antibiotic use in the European Union. Lancet 2001;357: Malfertheiner P, Megraud F, O Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maasstricht III Consensus Report. Gut 2007;6: Dixon MF, Genta RM, Yardley JH, et al. Participants in the International Workshop on the Histopathology of Gastritis, Houston 1994: classification and grading of gastritis. The updated Sydney system. Am J Surg Pathol 1996;20: Study highlights What is current knowledge: c H pylori eradication is becoming increasingly mote difficult to achieve due to increasing prevalence of antimicrobial resistant H pylori strains. c Prevalence of antimicrobial resistant H pylori strains vary from region to region. c First-line treatment should take into account the prevalence of antimicrobial-resistant H pylori strains in a given area. What is new here: c Failure to eradicate H pylori infection is associated with a significant increase in the prevalence of H pylori strains resistant to the most commonly used antimicrobials. c Eradication failures lead to the development of H pylori strains with multiple antimicrobial resistance. c Regimens other than standard triple therapy should be considered as first-line treatment in areas with high primary resistance to clarithromycin or metronidazole. 12. Iovene MR, Romano M, Pilloni AP, et al. Prevalence of antimicrobial resistance in eighty clinical isolates of Helicobacter pylori. Chemotherapy 1999;45: Megraud F and Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007;20: Chey WD, Wong BCJ, the Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102: Gerrits MM, van Vliet AHM, Kuipers E, et al. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. Lancet Infect Dis 2006;6: Huang J, Hunt RH. The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxicillin or metronidazole. Aliment Pharmacol Ther 1999;13: Romano M, Marmo R, Cuomo A, et al. Pretreatment antimicrobial susceptibility testing is cost-saving in the eradication of Helicobacter pylori. Clin Gastroenterol Hepatol 2003;1: Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006;23: Saad R, Shoenfeld P, Hyungjin MK, et al. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a metaanalysis. Am J Gastroenterol 2006;3: Colado MC, Gonzalez A, Gonzalez R, et al. Antimicrobial peptides are among the antagonistic metabolites produced by bifidobacterium against Helicobacter pylori. Int J Antimicrob Agents 2005;25: Bergonzelli GE, Donnicola D, Porta N, et al. Essential oils as components of a dietbased approach to management of Helicobacter pylori infection. Antimicrob Agents Chemother 2003;47: Stojiljkovic I, Evavold BD, Kumar V. Antimicrobial activity of porphyrins. Expert Opin Invest Drugs 2001;10: Vaira D, Zullo a, Vakil N, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Int Med 2007;146: Francavilla R, Lionetti E, Castellaneta SP, et al. Improved efficacy of 10-day sequential treatment for Helicobacter pylori eradication in children: a randomized trial. Gastroenterology 2005;129: J Clin Pathol 2008;000:1 5. doi: /jcp
5 cp60392 Module 1 Journal of Clinical Pathology 28/8/08 12:38:25 Topics: Authors Queries Journal: Journal of Clinical Pathology Paper: cp60392 Title: Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates Dear Author During the preparation of your manuscript for publication, the questions listed below have arisen. Please attend to these matters and return this form with your proof. Many thanks for your assistance Query Reference Query Remarks 1 You have opted not to pay a fee to make your article free online (Unlocked). If you wish to change your mind, please indicate this clearly and provide invoice address and contact details when you return your proofs. This is the last point in the production process where you can choose to Unlock your paper; the cost of this service is 1,200/$2,220/J1,775 (+VAT) and further details can be found at 2 I have define MIC50 and MIC90 in table 2 footnote. Please check 3 In table 2: 0016 to Why the leading zeros ( 00 )? Please clarify 4 Sentence Also, sequential therapy using PPI and amoxicillin for 5 days followed by PPI plus clarithromycin and tinidazole for 5 more days. does not make sense. Please check and reword. J Clin Pathol 2008;000:1 5. doi: /jcp
The annual incidence of peptic ulcer disease in developed
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2003;1:273 278 Pretreatment Antimicrobial Susceptibility Testing Is Cost Saving in the Eradication of Helicobacter pylori MARCO ROMANO,* RICCARDO MARMO, ANTONIO
More informationWhat is the status of Sequential Therapy Versus Standard Triple- Drug Therapy in peptic ulcer disease in eradicating H pylori?
What is the status of Sequential Therapy Versus Standard Triple- Drug Therapy in peptic ulcer disease in eradicating H pylori? Sequential Therapy Versus Standard Triple- Drug Therapy for Helicobacter pylori
More informationHelicobacter pylori Eradication Therapy Success Regarding Different Treatment Period Based on Clarithromycin or Metronidazole Triple-Therapy Regimens
Helicobacter ISSN 1523-5378 Filipec Blackwell Oxford, HEL 1083-4389 1523-5378 Journal XXX Original H. 2008 pylori Kanizaj compilation The UK Eradication Publishing Article Authors et al. Ltd 2008 Therapy
More informationTreating H. pylori in 2016
Treating H. pylori in 2016 William D. Chey, MD, FACG Professor of Medicine University of Michigan The Case: A 38 yo Russian man presents with recurrent epigastric pain which occurs after meals and sometimes
More informationEfficacy and Tolerability of a Third-Line, Levofloxacin-Based, 10-Day Sequential Therapy in Curing Resistant Helicobacter Pylori Infection
ORIGInAL PAPERs Efficacy and Tolerability of a Third-Line, Levofloxacin-Based, 10-Day Sequential Therapy in Curing Resistant Helicobacter Pylori Infection Antonio Tursi 1, Marcello Picchio 2, Walter Elisei
More informationCOMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION
Phil J Gastroenterol 2006; 2: 25-29 COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION Marianne P Collado, Ma Fatima P Calida, Peter P Sy,
More informationHelicobacter pylori: Diagnosis, treatment and risks of untreated infection
Helicobacter pylori: Diagnosis, treatment and risks of untreated infection Klaus Mönkemüller Department of Gastroenterology, Hepatology und Infectius Diseases Otto-von-Guericke University, Magdeburg bb
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Adherence, to bismuth quadruple therapy, 543 546 Adjuvant therapy, probiotics as, 567 569 Age factors, in gastric cancer, 611 612, 616 AID protein,
More informationMaastricht Ⅴ /Florence
2016 21 10 577 Maastricht Ⅴ /Florence 200001 2015 10 8 9 Maastricht V 1 / 2 3 4 / 5 Maastricht Ⅴ Interpretation of Management of Helicobacter pylori Infection the Maastricht Ⅴ / Florence Consensus Report
More informationTreatment of Helicobacter pylori Infection
Treatment of Helicobacter pylori Infection Epidemiology of H. pylori infection (North America) Which are the high risk groups? Epidemiology of H. pylori infection (North America) Which are the high risk
More informationHelicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35.
An Update on Helicobacter pylori and Its Treatment Trenika Mitchell, PharmD, BCPS Clinical Assistant Professor University of Kentucky College of Pharmacy October 18, 2008 Objectives Review the epidemiology
More informationAcid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs Prof. Sheila Crowe
Acid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs 1 Division of Gastroenterology UC San Diego School of Medicine Clinical presentations of Helicobacter pylori infection
More informationACG Clinical Guideline: Treatment of Helicobacter pylori Infection
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection William D. Chey, MD, FACG 1, Grigorios I. Leontiadis, MD, PhD 2, Colin W. Howden, MD, FACG 3 and Steven F. Moss, MD, FACG 4 1 Division
More informationEDUCATION PRACTICE. Persistent Helicobacter pylori Infection After a Course of Antimicrobial Therapy What s Next? Clinical Scenario.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:1086 1090 EDUCATION PRACTICE Persistent Helicobacter pylori Infection After a Course of Antimicrobial Therapy What s Next? RICHARD J. SAAD* and WILLIAM D.
More informationHelicobacter pylori resistance in the Netherlands: a growing problem?
ORIGINAL ARTICLE Helicobacter pylori resistance in the Netherlands: a growing problem? R. Ruiter 1,2 *, H.F. Wunderink 3, R.A. Veenendaal 5, L.G. Visser 4, M.G.J. de Boer 4 Departments of 1 Internal Medicine,
More informationPerspectives from Viet Nam
International Symposium I (Management of antibiotics-resistant Helicobacter pylori infection) Perspectives from Viet Nam Vu Van Khien 1,HoDangQuyDung 2, Tran Thanh Binh 2 1 Department of GI Endoscopy,
More informationHelicobacter pylori Improved Detection of Helicobacter pylori
DOI:http://dx.doi.org/10.7314/APJCP.2016.17.4.2099 RESEARCH ARTICLE Improved Detection of Helicobacter pylori Infection and Premalignant Gastric Mucosa Using Conventional White Light Source Gastroscopy
More informationPATHOGENESIS AND CURRENT TREATMENT OF H. PYLORI INFECTION. Jiannis Vlachogiannakos
PATHOGENESIS AND CURRENT TREATMENT OF H. PYLORI INFECTION Jiannis Vlachogiannakos Assistant Professor of Gastroenterology Medical School, University of Athens, Laiko General Hospital Helicobacter Pylori
More informationLow Dose Furazolidone for Eradication of H- pylori Instead of Clarithromycin: A Clinical Trial
Global Journal of Health Science; Vol. 7, No. 1; 2015 ISSN 1916-9736 E-ISSN 1916-9744 Published by Canadian Center of Science and Education Low Dose Furazolidone for Eradication of H- pylori Instead of
More informationEfficacy of standard triple therapy versus bismuth-based quadruple therapy for eradication of Helicobacter Pylori infection
Efficacy of standard triple therapy versus bismuth-based quadruple therapy for eradication of Helicobacter Pylori infection Ramin Talaie Modarress Hospital, Shahid Beheshti University of Medical Sciences,
More informationSusceptibility of Helicobacter Pylori to Antibiotics: a Study of Prevalence in Patients with Dyspepsia in Quito, Ecuador
DOI: https://doi.org/.5/57.7 Susceptibility of Helicobacter Pylori to Antibiotics: a Study of Prevalence in Patients with Dyspepsia in Quito, Ecuador Jorge Reyes Ch., Katherine Guzmán, Eduardo Morales,
More informationProton Pump Inhibitors Drug Class Prior Authorization Protocol
Proton Pump Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review
More informationProton pump inhibitor (proton pump inhibitor)-based triple therapies using clarithromycin in combination SUMMARY INTRODUCTION
Aliment Pharmacol Ther 2003; 18: 799 804. doi: 10.1046/j.1365-2036.2003.01764.x Esomeprazole-based one-week triple therapy with clarithromycin and metronidazole is effective in eradicating Helicobacter
More informationThe term biofilm describes the structurally complex bacterial BRIEF COMMUNICATION
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:817 820 BRIEF COMMUNICATION Biofilm Demolition and Antibiotic Treatment to Eradicate Resistant Helicobacter pylori: A Clinical Trial GIOVANNI CAMMAROTA,*
More informationEradication of H. pylori Infection in Patients Allergic to Penicillin Using Triple Therapy with a PPI, Metronidazole and Sitafloxacin
CASE REPORT Eradication of H. pylori Infection in Patients Allergic to Penicillin Using Triple Therapy with a PPI, Metronidazole and Sitafloxacin Takahisa Furuta 1, Mitsushige Sugimoto 2, Mihoko Yamade
More informationCHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS. 1. Which of the following is not a common cause of peptic ulcer disease (PUD)?
CHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS 1. Which of the following is not a common cause of peptic ulcer disease (PUD)? A. Chronic alcohol ingestion B. Nonsteroidal antiinflammatory
More informationHelicobacter pylori 幽門螺旋桿菌 馬偕紀念醫院新竹分院一般內科, 肝膽腸胃科陳重助醫師
Helicobacter pylori 幽門螺旋桿菌 馬偕紀念醫院新竹分院一般內科, 肝膽腸胃科陳重助醫師 Hp : Helicobacter pylori Part 1. Pathophysiology and immune response Pathogenesis of Hp infection Part 2. Clinical manifestation Part 3. Dx tests for
More informationGASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali
GASTROINTESTINAL AND ANTIEMETIC DRUGS Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS by: Shaema M. Ali There are four common medical conditions involving the GI system 1) peptic ulcers
More informationAntimicrobial Resistance of Helicobacter pylori Clinical Strains in the Last 10 Years
Polish Journal of Microbiology 2009, Vol. 58, No 4, 301 305 ORIGINAL PAPER Antimicrobial Resistance of Helicobacter pylori Clinical Strains in the Last 10 Years EWA ANDRZEJEWSKA, ANDRZEJ SZKARADKIEWICZ*,
More informationHelicobacter and gastritis
1 Helicobacter and gastritis Dr. Hala Al Daghistani Helicobacter pylori is a spiral-shaped gram-negative rod. H. pylori is associated with antral gastritis, duodenal (peptic) ulcer disease, gastric ulcers,
More informationManagement of dyspepsia and of Helicobacter pylori infection
Management of dyspepsia and of Helicobacter pylori infection The University of Nottingham John Atherton Wolfson Digestive Diseases Centre University of Nottingham, UK Community management of dyspepsia
More informationPEPTIC ULCER DISEASE JOHN R SALTZMAN, MD. Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School
PEPTIC ULCER DISEASE JOHN R SALTZMAN, MD Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School No disclosures Disclosures Overview Causes of peptic ulcer disease
More informationManagement of H. pylori Resistance
Management of H. pylori Resistance Manfred Kist, Erik Glocker, Nicole Wüppenhorst, Beate Hobmaier National Reference Centre for Helicobacter pylori Institute of Medical Microbiology and Hygiene Freiburg,
More informationTreatment for H. pylori Infection. New Challenges With Antimicrobial Resistance
CLINICAL REVIEW Treatment for H. pylori Infection New Challenges With Antimicrobial Resistance Nimish Vakil, MD, FACP, FACG, AGAF, FASGE* and Dino Vaira, MDw Abstract: The treatment of Helicobacter pylori
More informationDisclosures. Co-founder and Chief Science Officer, TechLab
H. pylori testing Disclosures Co-founder and Chief Science Officer, TechLab Learning Objectives Evaluate the appropriate testing methodology by balancing performance, economics, and workflow. Discuss the
More informationThe significance of Helicobacter pylori in the approach of dyspepsia in primary care Arents, Nicolaas Lodevikus Augustinus
University of Groningen The significance of Helicobacter pylori in the approach of dyspepsia in primary care Arents, Nicolaas Lodevikus Augustinus IMPORTANT NOTE: You are advised to consult the publisher's
More informationSitafloxacin activity against Helicobacter pylori including isolates with gyra. Key words: Helicobacter pylori, sitafloxacin, antimicrobial activity,
AAC Accepts, published online ahead of print on 20 April 2009 Antimicrob. Agents Chemother. doi:10.1128/aac.01552-08 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationResearch Article Performance of Routine Helicobacter pylori Invasive Tests in Patients with Dyspepsia
Gastroenterology Research and Practice Volume 2013, Article ID 184806, 5 pages http://dx.doi.org/10.1155/2013/184806 Research Article Performance of Routine Helicobacter pylori Invasive Tests in Patients
More informationSensitivity to nitazoxanide among metronidazole resistant Helicobacter pylori strains in patients with gastritis
Original Article Medical Journal of the Islamic Republic of Iran (MJIRI) Iran University of Medical Sciences Sensitivity to nitazoxanide among metronidazole resistant Helicobacter pylori strains in patients
More informationA Pilot Study of Helicobacter pylori Eradication Using a Polymerase Chain Reaction-based Test for Clarithromycin Resistance
ORIGINAL ARTICLE ISSN 1738-3331, https://doi.org/10.7704/kjhugr.2017.17.4.200 The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2017;17(4):200-207 A Pilot Study of Helicobacter pylori
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: helicobacter_pylori_testing 01/01/2019 N/A 01/01/2020 01/01/2019 Policy Effective April 1, 2019 Description
More informationRole of antimicrobial susceptibility testing on ef cacy of triple therapy in Helicobacter pylori eradication
Aliment Pharmacol Ther 2000; 14: 1639±1643. Role of antimicrobial susceptibility testing on ef cacy of triple therapy in Helicobacter pylori eradication S. TORACCHIO*, L. CELLINI, E.DICAMPLI, G.CAPPELLO*,M.G.MALATESTA*,A.FERRI*,
More informationRESEARCH ARTICLE. Abstract. Introduction
DOI:10.22034/APJCP.2017.18.4.927 Outcomes of a Randomized Controlled Trial Comparing Modified High Dose Omeprazole RESEARCH ARTICLE Outcomes of a Randomized Controlled Trial Comparing Modified High Dose
More informationCorrelation Between Endoscopic and Histological Findings in Different Gastroduodenal Lesion and its Association with Helicobacter Pylori
ORIGINAL ARTICLE Correlation Between Endoscopic and Histological Findings in Different Gastroduodenal Lesion and its Association with Helicobacter Pylori *A. Sultana 1, SM Badruddoza 2, F Rahman 3 1 Dr.
More informationPeptic Ulcer Disease Update
Peptic Ulcer Disease Update Col Pat Storms RAM 2005 Disclosure Information 84th Annual AsMA Scientific Meeting Col Patrick Storms I have no financial relationships to disclose. I will discuss the following
More informationHelicobacter pylori infection: antibiotic resistance and eradication rate in patients with gastritis showing previous treatment failures.
Short communication Helicobacter pylori infection: antibiotic resistance and eradication rate in patients with gastritis showing previous treatment failures. Maria Teresa Mascellino 1, Alessandra Oliva
More informationHelicobacter Pylori Testing HELICOBACTER PYLORI TESTING HS-131. Policy Number: HS-131. Original Effective Date: 9/17/2009
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationManagement of Helicobacter pylori infectiondthe Maastricht IV/ Florence Consensus Report
1 Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University of Magdeburg, Magdeburg, Germany 2 Department of Bacteriologie, INSERM U853, Université Bordeaux Segalen
More informationAmerican College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection
American Journal of Gastroenterology ISSN 0002-9270 C 2007 by Am. Coll. of Gastroenterology doi: 10.1111/j.1572-0241.2007.01393.x Published by Blackwell Publishing American College of Gastroenterology
More informationHelicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W.
UvA-DARE (Digital Academic Repository) Helicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W. Link to publication Citation for published
More informationThe diagnosis and management of H. pylori infection in Singapore
Singapore Med J 2017; 58(5): 234-240 doi: 10.11622/smedj.2017037 CMEArticle The diagnosis and management of H. pylori infection in Singapore Claire Alexandra Zhen Chew 1, MBChB, Tong Fong Lye 2, MBBS,
More informationHelicobacterPyloriandStepsforitsEliminationAReview
: F Diseases Volume 16 Issue 4 Version 1.0 Year 2016 Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Inc. (USA) Online ISSN: 2249-4618 & Print ISSN: 0975-5888
More informationHelicobacter pylori eradication an update on the latest therapies
Helicobacter pylori eradication an update on the latest therapies Author Yaxley, Julian, Chakravarty, Bhaskar Published 2014 Journal Title Australian Family Physician Copyright Statement 2014 Australian
More informationThe Nobel Prize in Physiology or Medicine for 2005
The Nobel Prize in Physiology or Medicine for 2005 jointly to Barry J. Marshall and J. Robin Warren for their discovery of "the bacterium Helicobacter pylori and its role in gastritis and peptic ulcer
More informationGastric atrophy: use of OLGA staging system in practice
Gastroenterology and Hepatology From Bed to Bench. 2016 RIGLD, Research Institute for Gastroenterology and Liver Diseases ORIGINAL ARTICLE Gastric atrophy: use of OLGA staging system in practice Mahsa
More informationDrug Class Monograph
Drug Class Monograph Class: Proton Pump Inhibitors Drugs: Aciphex Sprinkle (rabeprazole), Dexilant (dexlansoprazole), Lansoprazole, Nexium (esomeprazole capsule, esomeprazole granules), Omeprazole, Pantoprazole,
More informationMANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Routine endoscopic investigation of patients of any age, presenting with dyspepsia
More informationOriginal article J Bas Res Med Sci 2015; 2(4):45-50.
Comparison between the effectiveness of Furazolidone and Clarithromycin on eradication of helicobacter pylori among patients with peptic ulcer Asghar Rahmani 1, Ali Jafari Haidarloo 2, Hoda Mabrokzadeh
More informationPrevpac Pylera Omeclamox-Pak
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.21 Subject: -Pak Page: 1 of 5 Last Review Date: September 20, 2018 -Pak Description (lansoprazole,
More informationA Heaney, J S A Collins, RGPWatson, R J McFarland, K B Bamford, T C K Tham
186 Royal Victoria Hospital, Belfast, A Heaney J S A Collins Department of Medicine, Queen s University, Belfast, RGPWatson Ulster Hospital, Dundonald, R J McFarland T C K Tham Department of Microbiology
More informationUtility of In House made Rapid Urease Broth Test for Detection of Helicobacter pylori Infection in Resource Constraint Settings
Original article: Utility of In House made Rapid Urease Broth Test for Detection of Helicobacter pylori Infection in Resource Constraint Settings 1.Dr. Swati Rahul Dhope, 2. Dr. Sachinkumar Vasantrao Wankhede
More informationAssociation of Helicobacter pylori infection with Atrophic gastritis in patients with Dyspepsia
ADVANCES IN BIORESEARCH Adv. Biores., Vol 8 [3] May 2017: 137-141 2017 Society of Education, India Print ISSN 0976-4585; Online ISSN 2277-1573 Journal s URL:http://www.soeagra.com/abr.html CODEN: ABRDC3
More informationBee propolis in the treatment of Helicobacter pylori: in the right way to clinical applica5on
Bee propolis in the treatment of Helicobacter pylori: in the right way to clinical applica5on Marco Biagi UNIVERSITÀ DEGLI STUDI DI SIENA SOCIETA ITALIANA DI FITOTERAPIA Helicobacter pylori Helicobacter
More informationEfficacy of Proton Pump Inhibitor-based Triple Therapy and Bismuth-based Quadruple Therapy for Helicobacter pylori Eradication in Korean Children
pissn: 2234-8646 eissn: 2234-8840 http://dx.doi.org/10.5223/pghn.2012.15.4.237 Pediatric Gastroenterology, Hepatology & Nutrition 2012 December 15(4):237-242 Original Article PGHN Efficacy of Proton Pump
More informationHelicobacter pylori:an Emerging Pathogen
Bacteriology at UW-Madison Bacteriology 330 Home Page Helicobacter pylori:an Emerging Pathogen by Karrie Holston, Department of Bacteriology University of Wisconsin-Madison Description of Helicobacter
More informationHELICOBACTER PYLORI ERADICATION TREATMENT AND THE RISK OF GASTRIC AND OESOPHAGEAL CANCER
From the Department of Molecular Medicine and Surgery Karolinska Institutet, Stockholm, Sweden HELICOBACTER PYLORI ERADICATION TREATMENT AND THE RISK OF GASTRIC AND OESOPHAGEAL CANCER Eva Doorakkers Stockholm
More informationComparison of the Accuracy of Two Commercial Rapid Urase Tests, CLOtest and Pronto Dry, in Detecting Helicobacter pylori Infection ABSTRACT
Original Article Rojborwonwitaya J, Vijitjunyakul N THAI J GASTROENTEROL 2005 Vol. 6 No. 2 May - Aug. 2005 55 Comparison of the Accuracy of Two Commercial Rapid Urase Tests, CLOtest and Pronto Dry, in
More informationClinical Study Standard Triple Therapy versus Sequential Therapy in Helicobacter pylori Eradication: A Double-Blind, Randomized, and Controlled Trial
Gastroenterology Research and Practice Volume 2015, Article ID 818043, 5 pages http://dx.doi.org/10.1155/2015/818043 Clinical Study Standard Triple Therapy versus Sequential Therapy in Helicobacter pylori
More informationMalaysian Journal of Microbiology
Malaysian Journal of Microbiology, Vol xx(x) Special Issue xxxx, pp. xxx-xxx DOI: http://dx.doi.org/10.21161/mjm.xxxxxx Malaysian Journal of Microbiology Published by Malaysian Society for Microbiology
More informationHigh use of maintenance therapy after triple therapy regimes in Ireland
High use of maintenance therapy after triple therapy regimes in Ireland K Bennett, H O Connor, M Barry, C O Morain, J Feely Department of Pharmacology & Therapeutics Department of Gastroenterology Trinity
More informationMulticenter Survey of Routine Determinations of Resistance of Helicobacter pylori to Antimicrobials over the Last 20 Years (1990 to 2009) in Belgium
JOURNAL OF CLINICAL MICROBIOLOGY, June 2011, p. 2200 2209 Vol. 49, No. 6 0095-1137/11/$12.00 doi:10.1128/jcm.02642-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Multicenter
More informationAntibiotic resistance in Helicobacter pylori infection
Antibiotic resistance in Helicobacter pylori infection Francis Megraud haboratoire de Bacteriologie, Hopital Pellegrin, Bordeaux, France Resistance to antibiotics is considered as the primary reason for
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/48400
More informationTriple therapy versus sequential therapy for the first-line Helicobacter pylori eradication
Chang et al. BMC Gastroenterology (2017) 17:16 DOI 10.1186/s12876-017-0579-8 RESEARCH ARTICLE Open Access Triple therapy versus sequential therapy for the first-line Helicobacter pylori eradication Ji
More informationOriginal Policy Date
MP 2.04.38 Genetic Testing for Helicobacter pylori Treatment Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return
More informationHybrid therapy as first-line regimen for Helicobacter pylori eradication in a high clarithromycin resistance area: a prospective open-label trial
ORIGINAL ARTICLE Annals of Gastroenterology (2018) 31, 1-6 Hybrid therapy as first-line regimen for Helicobacter pylori eradication in a high clarithromycin resistance area: a prospective open-label trial
More informationHelicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W.
UvA-DARE (Digital Academic Repository) Helicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W. Link to publication Citation for published
More informationEvaluation of a new rapid immunoassay for the detection of Helicobacter pylori in faeces: a prospective pilot study
Aliment Pharmacol Ther 2005; 21: 485 489. doi: 10.1111/j.1365-2036.2005.02355.x Evaluation of a new rapid immunoassay for the detection of Helicobacter pylori in faeces: a prospective pilot study L. TREVISANI*,
More informationJJBS Jordan Journal of Biological Sciences
JJBS Jordan Journal of Biological Sciences Volume 4, Number 2, June 2011 ISSN 1995-6673 Pages 71-76 Prevalence of Helicobacter Pylori Gastritis at the North of Jordan N. M. Abu-Ahmad, A. Odeh and A-K.
More informationEvaluation of antimicrobial susceptibility of Helicobacter pylori to common antibiotics in Tabriz, northwest of Iran
Available online at www.scholarsresearchlibrary.com Annals of Biological Research, 2013, 4 (1):99-103 (http://scholarsresearchlibrary.com/archive.html) ISSN 0976-1233 CODEN (USA): ABRNBW Evaluation of
More informationRapidity of diagnosis and management of H. Pylori in the endoscopy unit at Mater Dei Hospital
Rapidity of diagnosis and management of H. Pylori in the endoscopy unit at Mater Dei Hospital Abstract Introduction: H.pylori infection has been associated with various gastric pathologies and its prevalence
More informationRifaximin Plus Levofloxacin-Based Rescue Regimen for the Eradication of Helicobacter pylori
Gut and Liver, Vol. 6, No. 4, October 2012, pp. 452-456 ORiginal Article Rifaximin Plus Levofloxacin-Based Rescue Regimen for the Eradication of Helicobacter pylori Sang-Pil Yun, Han Gyung Seon, Chang
More informationReview article: the global emergence of Helicobacter pylori antibiotic resistance
Alimentary Pharmacology and Therapeutics Review article: the global emergence of Helicobacter pylori antibiotic resistance I. Thung*,1, H. Aramin*,1, V. Vavinskaya*, S. Gupta,J.Y.Park, S. E. Crowe & M.
More informationReceived 17 August 2010/Returned for modification 7 December 2010/Accepted 16 December 2010
ANTIMICROBIAL AGENTS AND CHEMOTHERAY, Mar. 2011, p. 1123 1129 Vol. 55, No. 3 0066-4804/11/$12.00 doi:10.1128/aac.01131-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Genotypic
More information헬리코박터파일로리감염에서고용량및다빈도덱스란소프라졸과아모시실린이중치료 : 단일군전향연구
Korean J Gastroenterol Vol. 70 No. 4, 176-180 https://doi.org/10.4166/kjg.2017.70.4.176 pissn 1598-9992 eissn 2233-6869 ORIGINAL ARTICLE 헬리코박터파일로리감염에서고용량및다빈도덱스란소프라졸과아모시실린이중치료 : 단일군전향연구 박혜윤, 강은정, 김동근, 김기주,
More informationThe role of antisecretory drugs in the treatment of Helicobacter pylori infection
Aliment Pharmacol Ther 1997; 11 (Suppl. 1): 21 25. The role of antisecretory drugs in the treatment of Helicobacter pylori infection W. L. PETERSON Department of Internal Medicine, University of Texas
More informationRapid increase in the prevalence of metronidazole resistant Helicobacter pylori in the Netherlands.
Chapter 2 Rapid increase in the prevalence of metronidazole resistant Helicobacter pylori in the Netherlands. E.J.van der Wouden 1, A.A.van Zwet 2, J.C.Thijs 1, G.D.C.Vosmaer 3, J.A.J.Oom 4, A.de Jong
More information헬리코박터제균요법에있어서 CYP2C19 유전형이판토프라졸과라베프라졸포함치료법에미치는영향. Introduction 울산대학교의과대학서울아산병원소화기내과
The Korean Journal of Helicobacter and Upper Gastrointestinal Research Vol. 8, No. 1, 15-19, July 2008 Influence of CYP2C19 Polymorphism on Eradication of Helicobacter pylori: Comparison between Pantoprazole
More informationÐÑÏÓÊÅÊËÇÌÅÍÅÓ ÎÅÍÏÃËÙÓÓÅÓ ÁÍÁÊÏÉÍÙÓÅÉÓ ÅËËÇÍÙÍ ÅÑÅÕÍÇÔÙÍ
ÐÑÏÓÊÅÊËÇÌÅÍÅÓ ÎÅÍÏÃËÙÓÓÅÓ ÁÍÁÊÏÉÍÙÓÅÉÓ ÅËËÇÍÙÍ ÅÑÅÕÍÇÔÙÍ 205 206 ÐÑÏÓÊÅÊËÇÌÅÍÅÓ ÎÅÍÏÃËÙÓÓÅÓ ÁÍÁÊÏÉÍÙÓÅÉÓ ÅËËÇÍÙÍ ÅÑÅÕÍÇÔÙÍ EPITHELIAL CELL TURNOVER IN NON-DYSPLASTIC GASTRIC MUCOSA ADJACENT TO EARLY AND
More information- Helicobacter - THE EASE AND DIFFICULTY OF A NEW DISCOVERY. Robin Warren
- Helicobacter - THE EASE AND DIFFICULTY OF A NEW DISCOVERY Robin Warren EARLY DAYS First reports 100 years ago considered spirochaetes 1940 Freedburg saw curved organisms in the stomach 1954 Palmer: Freedburg
More informationHelicobacter pylori Eradication Therapy Research: Ethical Issues and Description of Results
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:1032 1036 PERSPECTIVE Helicobacter pylori Eradication Therapy Research: Ethical Issues and Description of Results DAVID Y. GRAHAM Department of Medicine,
More informationDownloaded from:
Allison, R; ecky, DM; Bull, M; Turner, K; Godbole, G; Mculty, CA (2016) Audit of Helicobacter pylori Testing in Microbiology aboratories in England: To Inform Compliance with ICE Guidance and the Feasibility
More informationTreating Helicobacter pylori effectively while minimizing misuse of antibiotics
REVIEW AKIKO SHIOTANI, MD, PhD Professor, Department of Internal Medicine, Kawasaki Medical School, Okayama, Japan EDUCATIONAL OBJECTIVE: Readers will treat Helicobacter pylori infections according to
More informationComparison of sequential therapy for eradication of Helicobacter pylori with standard triple therapy
Original articles Comparison of sequential therapy for eradication of Helicobacter pylori with standard triple therapy Martín Gómez Zuleta, 1 Christian Melgar Burbano, 2 William Otero Regino. 3 1 Assistant
More informationHelicobacter pylori Infection
The new england journal of medicine clinical practice Helicobacter pylori Infection Kenneth E.L. McColl, M.D. This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence
More informationGilles Jequier. Commercial Director Organobalance, a Novozymes Company
"Latest clinical Evidences showing that a proprietary Lactobacillus reuteri Strain can reduce the Symptoms associated with a Helicobacter pylori Infection" Gilles Jequier Commercial Director Organobalance,
More informationHELICOBACTER PYLORI UPDATE
HELICOBACTER PYLORI UPDATE PROF. TAWHEED MOWAFY DEAN OF AZAL FACULTY OF MEDICINE INTRODUCTION (H. pylori) is recognised as the most common chronic human bacterial infection,1 affecting up to 50% of the
More informationinstrument. When 13C-UBT positive value is greater than or equal to / - 0.4, the the subject can be 1. Data and methods details are as follows:
Application of 13 C-urea breath test in screening helicobacter pylori infection during health examination in Chengdu, Sichuan YANG Yan-hua. LIU Yu-ping. CHENG You-fu, SHUAI Ping. LU Qiao. ZHENG Xiao-xia,
More information